Western Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321

MT Newswires Live

11/21

D. Western Therapeutics Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of K-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.

The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.

Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2585736199"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585736199\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585736199?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 13:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585736199","market":"sg","top_or_hot":-1,"title":"Western Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321","media":"MT Newswires Live","content":"<html><body><p> D. Western <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.</p><p>The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.</p><p>Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Western Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWestern Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-21 13:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> D. Western <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.</p><p>The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.</p><p>Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2585736199","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585736199","pubTimestamp":1763704348,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"D. Western Therapeutics Institute  said the observation period has finished in one of two global Phase III trials of K-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","WRN":"西方铜金","BK4168":"多种金属与采矿","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Western Therapeutics表示Fuchs药物K-321全球试验观察阶段已完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"WRN":1.5},"content_text":"D. Western Therapeutics Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of K-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}